Anavex Life Sciences Corp (AVXL)

[Investor2014]

The purpose of the Ariana KEM analysis is to design the next trial optimally by knowing which patient profiles will respond well and stratify trial arms accordingly.

This is a new and intelligent way to reduce the risk of P3 trial failure, as per D. Perry on the call. So far we have only seen this Precision Medicine approach at work in Oncology, with Anavex being the first to take this approach together with Ariana in a CNS disease and then as complex as Alzheimers's.

This is quite different from the notion that data mining is being employed in a desperate attempt to squeeze plausible efficacy out of less than good results.

Medicine is tricky!